News Headlines Article

FDA approves Amgen’s heart failure drug Corlanor
Los Angeles Business Journal

The Food and Drug Administration has approved Amgen Inc.’s drug, Corlanor, to treat patients with chronic heart failure, a disease that leads to frequent hospitalizations and oftentimes death.

Thousand Oaks-based Amgen(Nasdaq: AMGN) said Corlanor is the first new chronic heart failure medicine approved by the FDA in nearly a decade. The FDA said it approved the use of Corlanor (ivabradine) on top of current standard of care beta blockers, for patients with moderate to severe heart failure and a resting heart rate of at least 70 beats per minute.